Emerging pharmacotherapies for the treatment of atrial fibrillation

References

• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–272.
   Web of Science ®Google Scholar
• Camm J, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Heart J. 2012;33:2719–2747.
   Google Scholar
• Lafuente-Lafuente C, Valembois L, Bergmann J-F, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2015;3:CD005049.
   PubMed Web of Science ®Google Scholar
• Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367:1587–1595.
   PubMed Web of Science ®Google Scholar
• Guerra F, Hohnloser SH, Kowey PR, et al. Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. Clin Cardiol. 2014;37:1–8.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Breithardt G, Bax J, et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace. 2016;18:37–50.
   PubMed Web of Science ®Google Scholar
• Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010;375:1212–1223.
   PubMed Web of Science ®Google Scholar
• Kopecky SL, Gersh BJ, McGoon, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med. 1987;317:669–674.
   PubMed Web of Science ®Google Scholar
• Heijman J, Voigt N, Dobrev D. New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol. 2013;9(1):71–88.
   PubMedGoogle Scholar
• Liu T, Li G, Li L, et al. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007;49:5.
   Web of Science ®Google Scholar
• Gungor B, Ekmekci A, Arman, et al. Assessment of interleukin-1 gene cluster polymorphisms in lone atrial fibrillation: new insight into the role of inflammation in atrial fibrillation. Pacing Clin Electrophysiol. 2013;36:1220–1227.
   PubMed Web of Science ®Google Scholar
• Richter B, Gwechenberger M, Socas, et al. Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin Res Cardiol. 2012;101:217–225.
   PubMed Web of Science ®Google Scholar
• Imazio M, Brucato A, Ferrazzi, et al.; COPPS Investigators. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124:2290–2295.
   PubMed Web of Science ®Google Scholar
• Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4:252–256.
   PubMedGoogle Scholar
• Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm. 2007;4(suppl 3):S61–S64.
   PubMed Web of Science ®Google Scholar
• Tan AY, Zhou S, Gholmieh G, et al. Spontaneous autonomic nerve activity and paroxysmal atrial tachyarrhythmias (abstract). Heart Rhythm. 2006;3:S184.
   Google Scholar
• Patel C, Yan G-X, Kowey PR. Dronedarone. Circulation. 2009;120:636–644.
   PubMed Web of Science ®Google Scholar
• Singh Bramah N, Connolly SJ; for the EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(10):987–999.
   PubMed Web of Science ®Google Scholar
• Køber L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678–2687.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJGM, Van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–678.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crijns HJGM, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: a placebo-controlled, double- blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174–1180.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJGM, Van Eickels M, et al. Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J. 2010;31:1717–1721.
   PubMed Web of Science ®Google Scholar
• Davy J-M, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the ef cacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156:527e1–9.
   Web of Science ®Google Scholar
• Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268–2276.
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double- blind, parallel-group study to evaluate the ef cacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(16):597–605.
   PubMedGoogle Scholar
• Guerra F, Brambatti M, Matassini MV, et al. Amiodarone and digitalis: an odd couple in a tachycardiomyopathic patient. Case Rep Intern Med. 2014;1:1.
   Google Scholar
• Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481–1487.
   PubMed Web of Science ®Google Scholar
• Roy D, Rowe BH, Stiell IG, et al.; CRAFT investigators. A randomized controlled trial of RSD 1235, a novel antiarrythmic agent in 14 treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004;44(12):2355–2361.
   PubMed Web of Science ®Google Scholar
• Cardiome Pharma Corp. Vernakalant. Available from: www.cardiome.com
   Google Scholar
• Roy D, Pratt CM, Torp-Pedersen C, et al.; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a Phase 3, randomized, placebo-controlled 16 trial. Circulation. 2008; 117(12):1518–1525.
   PubMed Web of Science ®Google Scholar
• Pratt CM, Roy D, Torp-Pederson C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010;106(17):1277–1283.
   PubMedGoogle Scholar
• Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant Hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circulation. 2009;2:652–659.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol [Internet]. 2011 Jan 18 [cited 2017 Mar 12];57(3):313–321.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Toft E, Torp-Pedersen C, et al. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. Europace. 2012 Jun 1 [cited 2017 Mar 12];14(6):804–809.
   PubMed Web of Science ®Google Scholar
• Stiell IG, Roos JS, Kavanagh KM, et al. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010;159:1095–1101.
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Sicouri S, Di Diego JM, et al. Synergistic effect of the combination of dronedarone and ranolazine to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56:1216–1224.
   PubMed Web of Science ®Google Scholar
• Reiffel JA, Camm AJ, Belardinelli L, et al. The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circulation. 2015 Jul 30;8:1048–1056.
   PubMed Web of Science ®Google Scholar
• Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN–TIMI (metabolic efficiency with ranolazine for less ischemia in non–ST-segment elevation acute coronary syndromes) 36 trial. J Am Coll Cardiol. 2009;4:1510–1516.
   Google Scholar
• Guerra F, Romandini A, Barbarossa A, et al. Ranolazine for rhythm control in atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2017;227:284–291.
   PubMed Web of Science ®Google Scholar
• Murdock DK, Kersten M, Kaliebe J, et al. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible ‘pill in the pocket’ approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009;9:260–267.
   PubMedGoogle Scholar
• De Ferrari GM, Maier LS, Mont L et al. Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm. 2015;12(5):872–878.
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Kossyvakis C, et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol. 2012;60:1790–1796.
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Efremidis M, et al. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life. Heart Rhythm. 2014;11:620–628.
   PubMed Web of Science ®Google Scholar
• Lemola K, Hall B, Cheung P, et al. Mechanisms of recurrent atrial fibrillation after pulmonary vein isolation by segmental ostial ablation. Heart Rhythm. 2004;1:197–202.
   PubMed Web of Science ®Google Scholar
• Kowalski M, Grimes MM, Perez FJ, et al. Histopathologic characterization of chronic radiofrequency ablation lesions for pulmonary vein isolation. J Am Coll Cardiol. 2012;59:930–938.
   PubMed Web of Science ®Google Scholar
• Tesic D1, Kostic M, Paunovic D et al. Analysis of the cost–effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia. Kardiologia Polska. 2015;73(4):287–295. doi:10.5603/KP.a2014.0228.
   PubMed Web of Science ®Google Scholar
• Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation—results for Canada, Italy, Sweden and Switzerland. Eur J Health Econ. 2013 June;14(3):481–493.
   PubMed Web of Science ®Google Scholar
• Stoneman P, Gilligan P, Mahon P, et al. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge. Ir J Med Sci. 2017;186:903–908. doi:10.1007/s11845-017-1576-1.
   PubMed Web of Science ®Google Scholar
• Buccelletti F, Iacomini P, Botta G, et al. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis. J Clin Pharmacol. 2012;52:1872–1878.
   PubMed Web of Science ®Google Scholar
• Hancox JC, James AF, Marrion NV, et al. Novel ion channel targets in atrial fibrillation. Expert Opin Ther Targets. 2016 Aug;20(8):947–958.
   PubMed Web of Science ®Google Scholar
• Liu J, Noble PJ, Xiao G, et al. Role of pacemaking current in cardiac nodes: insights from a comparative study of sinoatrial node and atrioventricular node. Prog Biophys Mol Biol. 2008;96:294–304.
   PubMed Web of Science ®Google Scholar
• Schweizer P, Becker R, Katus H, et al. Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des Dev Ther. 2011;5:27–39.
   PubMed Web of Science ®Google Scholar
• Voigt N, Trausch A, Knaut M, et al. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(5):472–480.
   PubMed Web of Science ®Google Scholar
• Makary S, Voigt N, Maguy A, et al. Differential Protein Kinase C isoform regulation and increased constitutive activity of acetylcholine-regulated potassium channels in atrial remodeling. Circ Res. 2011;109(9):1031–1043.
   PubMed Web of Science ®Google Scholar
• Dierk T, Kathofer S, Zhang W, et al. Acute effects of dronedarone on both components of the cardiac delayed rectifier Kþ current, HERG and KvLQT1/minK potassium channels. Br J Pharmacol. 2003;140:996–1002.
   PubMed Web of Science ®Google Scholar
• Sun W, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (sr33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999;100:2276–2281.
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Wolbrette DL, Samii S, et al. Vernakalant—a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs. 2008;17:805–810.
   PubMed Web of Science ®Google Scholar
• Eldstrom J, Wang Z, Xu H, et al. The molecular basis of high-affinity binding of the antiarrhythmic compound Vernakalant (RSD1235) to Kv1. 5 channels. Mol Pharmacol. 2007;72(6):1522–1534.
   PubMed Web of Science ®Google Scholar
• Wettwer E, Christ T, Endig S, et al. The new antiarrhythmic drug Vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Cardiovasc Res. 2013;98:145.
   PubMed Web of Science ®Google Scholar
• Hove-Madsen L, Llach A, Bayes-Genìs A, et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation. 2004;110(11):1358.
   PubMed Web of Science ®Google Scholar
• Voigt N, Li N, Wang Q, et al. Enhanced sarcoplasmic reticulum Ca2 leak and increased Na -Ca2 exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation. 2012;125(17):2059.
   PubMed Web of Science ®Google Scholar
• Voigt N, Heijman J, Wang Q, et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 2014;129(2):145–156.
   PubMed Web of Science ®Google Scholar
• Fedida D. Vernakalant (RSD1235): a novel, atrial-selective anti fibrillatory agent. Expert Opin Investig Drugs. 2007;16:519–532.
   PubMed Web of Science ®Google Scholar
• Tian D, Frishman WH. A new drug to treat patients with acute onset atrial fibrillation. Cardiol Rev. 2011;19(1):41–44.
   PubMed Web of Science ®Google Scholar
• Mao ZL, Wheeler JJ, Clohs L, et al. Pharmacokinetics of novel atrialselective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009;49:17–29.
   PubMed Web of Science ®Google Scholar
• Cheng JWM, Rybak I. Pharmacotherapy 13 options in atrial fibrillation: focus on vernakalant. Clin Med Ther. 2009;1:215–230.
   Google Scholar
• Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116:1449–1457.
   PubMed Web of Science ®Google Scholar
• Dittrich HC, Feld GK, Bahnson TD, et al. COR-ART: a multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. Heart Rhythm. 2015;12:1105–1112.
   PubMed Web of Science ®Google Scholar
• Lacerda AE, Kuryshev YA, Yan GX, et al. Vanoxerine: cellular mechanism of a new antiarrhythmic. J Cardiovasc Electrophysiol. 2010;21:301–310.
   PubMed Web of Science ®Google Scholar
• Dhimolea E. Canakinumab. MAbs. 2010;2:3–13.
   PubMed Web of Science ®Google Scholar
• Milnes JT, Louis L, Rogers M, et al. The atrial antiarrhythmic drug XEN-D0101 selectively inhibits the human ultra-rapid delayed-rectifier potassium current (IKur) over other cardiac ion channels. Circulation. 2008;118:S342.
   Web of Science ®Google Scholar
• Ford J, Milnes J, Wettwer E, et al. Electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013;61:408–415.
   PubMed Web of Science ®Google Scholar
• Mueller J, Wettwer E, Ford J, et al. Frequency-dependent effects of the selective IKur blocker XEN-D0103 in human atrial tissue. Europace. 2013;15:S2.
   Google Scholar
• Morey TE, Seubert CN, Raatikainen MJ, et al. Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol Exp Ther. 2001;297:260–266.
   PubMed Web of Science ®Google Scholar
• Arya A, Silberbauer J, Teichman SL, et al. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace. 2009;11:458–464.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Nagarakanti R, Lubinski A, et al.; PASCAL Investigators. A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012;34:1–9.
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Kossyvakis C, et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol. 2013;112:684–687.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Pfeffer MA, Rouleau J, et al.; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659–667.
   PubMed Web of Science ®Google Scholar
• Aleong RG, Sauer WH, Sauer WH, et al. Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013;1:338–344.
   PubMed Web of Science ®Google Scholar
• Nia AM, Caglayan E, Gassanov N, et al. Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation. PLoS One. 2010;5:e11421.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Fiuzat M, Carson PE, et al. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. PLoS One. 2012;7:e44324.
   PubMed Web of Science ®Google Scholar
• Liggett SB, MialetPerez J, ThaneemitChen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103:11288–11293.
   PubMed Web of Science ®Google Scholar
• Oral H, Crawford T, Frederick M, et al. Inducibility of paroxysmal atrial fibrillation by isoproterenol and its relation to the mode of onset of atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19:466–470.
   PubMed Web of Science ®Google Scholar
• Lalevée N, Nargeot J, Barrére-Lemaire S, et al. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol. 2003;14:885–890.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Wiedmann F, Voigt N, et al. Upregulation of K2P3.1 K+ current causes action potential shortening in patients with chronic atrial fibrillation. Circulation. 2015;132(2):82–92.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Wiedmann F, Zhou W, et al. Inverse remodelling of K2P3.1 K1 channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. Eur Heart J. 2017;38(22):1764–1774.
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline) 2011 writing group members. Jacc. 2011;57:223–242.
   Google Scholar
• Diemberger I, Massaro G, Reggiani ML, et al. Outcomes with dronedarone in atrial fibrillation: what differences between real-world practice and trials? A meta-analysis and meta-regression analysis. Curr Pharm Des. 2017;23(6):944–951.
   PubMed Web of Science ®Google Scholar
• Reddy M, Vallakati A, Kanmanthareddy A, et al. Vernakalant for rapid cardioversion of recent onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol. 2014;63:A426.
   Web of Science ®Google Scholar
• Conde D, Costabel JP, Alves de Lima A. Recent-onset atrial fibrillation in patients with left ventricular dysfunction: amiodarone or vernakalant? Can J Cardiol. 2013;29:1330.e11–1330.e12.
   Web of Science ®Google Scholar
• Conde D, Costabel JP, Caro M, et al. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J Cardiol. 2013;168:2423–2425.
   PubMed Web of Science ®Google Scholar
• Guerra F, Matassini MV, Scappini L, et al. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2014;12:1067–1075.
   PubMedGoogle Scholar